BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33885036)

  • 1. Two Cases of Veno-occlusive Disease/Sinusoidal Obstruction Syndrome After Thioguanine Treatment for Acute Lymphoblastic Leukemia.
    Gruhn B; Brodt G; Mentzel HJ; Ernst J
    J Pediatr Hematol Oncol; 2022 Mar; 44(2):e572-e575. PubMed ID: 33885036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of defibrotide in blood and marrow transplantation.
    Richardson PG; Carreras E; Iacobelli M; Nejadnik B
    Blood Adv; 2018 Jun; 2(12):1495-1509. PubMed ID: 29945939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
    Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
    Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
    Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
    Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
    Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients.
    Corbacioglu S; Kernan NA; Pagliuca A; Ryan RJ; Tappe W; Richardson PG
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1342-1349. PubMed ID: 32200121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
    Richardson PG; Triplett BM; Ho VT; Chao N; Dignan FL; Maglio M; Mohty M
    Expert Rev Clin Pharmacol; 2018 Feb; 11(2):113-124. PubMed ID: 29301447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnosis and treatment of sinusoidal obstruction syndrome (veno-occlusive disease)].
    Kikuta A
    Rinsho Ketsueki; 2021; 62(8):1256-1264. PubMed ID: 34497214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide.
    Gómez-Centurión I; Bailén R; Oarbeascoa G; Muñoz C; Luque AÁ; Boyra ME; Calleja E; Rincón D; Dorado N; Barzallo P; Anguita J; Díez-Martín JL; Kwon M
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2089-2097. PubMed ID: 32791193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation.
    Richardson PG; Smith AR; Kernan NA; Lehmann L; Ryan RJ; Grupp SA
    Transplant Cell Ther; 2021 Jan; 27(1):88.e1-88.e6. PubMed ID: 32950693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.
    Corbacioglu S; Richardson PG
    Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):885-898. PubMed ID: 28825848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
    Farina M; Scaini MC; Facchinetti A; Leoni A; Bernardi S; Catoni C; Morello E; Radici V; Frioni F; Campodonico E; Traverso G; Cavallaro G; Olivieri A; Galieni P; Renzo ND; Patriarca F; Carluccio P; Skert C; Maffini E; Pellizzeri S; Campisi G; Re F; Benedetti E; Rosato A; Almici C; Chiusolo P; Peccatori J; Malagola M; Poggiana C; Russo D
    Transplant Cell Ther; 2024 Jun; 30(6):580.e1-580.e14. PubMed ID: 38582286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sinusoidal Obstruction Syndrome During Chemotherapy of Pediatric Cancers and its Successful Management With Defibrotide.
    Kizilocak H; Dikme G; Özdemir N; Kuruğoğlu S; Adaletli İ; Erkan T; Celkan T
    J Pediatr Hematol Oncol; 2017 Oct; 39(7):e373-e376. PubMed ID: 28859028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.
    Kernan NA; Richardson PG; Smith AR; Triplett BM; Antin JH; Lehmann L; Messinger Y; Liang W; Hume R; Tappe W; Soiffer RJ; Grupp SA
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27269. PubMed ID: 29873895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant.
    Nauffal M; Kim HT; Richardson PG; Soiffer RJ; Antin JH; Cutler C; Nikiforow S; Gooptu M; Koreth J; Romee R; Ho VT
    Blood Adv; 2022 Jan; 6(1):181-188. PubMed ID: 34666352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure.
    Richardson PG; Grupp SA; Pagliuca A; Krishnan A; Ho VT; Corbacioglu S
    Int J Hematol Oncol; 2017 Nov; 6(3):75-93. PubMed ID: 30302228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
    Corbacioglu S; Kernan N; Lehmann L; Brochstein J; Revta C; Grupp S; Martin P; Richardson PG
    Expert Rev Hematol; 2012 Jun; 5(3):291-302. PubMed ID: 22780209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.
    Picod A; Bonnin A; Battipaglia G; Giannotti F; Ruggeri A; Brissot E; Malard F; Médiavilla C; Belhocine R; Vekhoff A; Gueye MS; Lapusan S; Adaeva R; Isnard F; Legrand O; Baylatry MT; Joly AC; Labopin M; Duléry R; Mohty M
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1471-1475. PubMed ID: 29477779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Advances in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease.
    Mavrikou I; Chatzidimitriou D; Skoura L; Nikolousis E; Sakellari I; Gavriilaki E
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of defibrotide in the treatment of patients with severe veno-occlusive disease/sinusoidal obstructive syndrome with multiorgan dysfunction following hematopoietic cell transplantation in Spain.
    Carcedo Rodriguez D; Artola Urain T; Chinea Rodriguez A; García Torres E; González Vicent M; Gutiérrez García G; Regueiro García A; Calvo Hidalgo M; Villacampa A
    J Med Econ; 2021; 24(1):628-636. PubMed ID: 33858278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.